샘플 요청 목록

 카트 문의
시장보고서
상품코드
1757971

안데르센-타윌 증후군(ATS) 시장

Andersen-Tawil Syndrome (ATS)
발행일: | 리서치사: Market Glass, Inc. (Formerly Global Industry Analysts, Inc.) | 페이지 정보: 영문 276 Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

세계의 안데르센-타윌 증후군(ATS) 시장은 2030년까지 310만 달러에 달할 전망

2024년에 220만 달러로 추정되는 세계의 안데르센-타윌 증후군(ATS) 시장은 2024-2030년의 분석 기간에 CAGR 5.7%로 성장하며, 2030년에는 310만 달러에 달할 것으로 예측됩니다. 이 리포트에서 분석한 부문의 하나인 1형 질환은 CAGR 4.5%를 기록하며, 분석 기간 종료시에는 180만 달러에 달할 것으로 예측됩니다. 2형 질환 부문의 성장률은 분석 기간 중 CAGR 7.4%로 추정됩니다.

미국 시장은 59만 9,500달러로 추정, 중국은 CAGR 8.7%로 성장할 것으로 예측

미국의 안데르센-타윌 증후군(ATS) 시장은 2024년에 59만 9,500달러로 추정됩니다. 세계 2위의 경제대국인 중국은 2024-2030년에 CAGR 8.7%로 추이하며, 2030년에는 61만 900달러의 시장 규모에 달할 것으로 예측됩니다. 기타 주목할 만한 지역별 시장으로는 일본과 캐나다가 있으며, 분석 기간 중 CAGR은 각각 2.8%와 5.5%로 예측됩니다. 유럽에서는 독일이 CAGR 3.7%로 성장할 것으로 예측됩니다.

세계의 안데르센-타윌 증후군(ATS) 시장 - 주요 동향과 촉진요인 정리

안데르센-타윌 증후군이 희귀질환 커뮤니티에서 주목받는 이유는 무엇인가?

안데르센-타윌 증후군은 매우 드문 질환이지만, 복잡한 증상과 진단상의 문제로 인해 연구자, 임상의사, 환자 지원 단체의 관심이 높아지고 있습니다. 상염색체 우성 유전인 이 질환은 주기적 마비, 특징적인 얼굴과 골격, 심장 부정맥의 세 가지 증상으로 특징지어지는데, 조기 발견과 효과적인 관리에 큰 걸림돌이 되고 있습니다. 기존에는 일반적인 질환과 증상이 중복되어 진단이 늦어지거나 오분류되는 경우가 많았으나, 유전자 검사와 임상적 인식의 발전으로 ATS가 인식되고 있습니다. 보다 정교한 표현형 분석 기술과 차세대 시퀀서의 등장으로 진단의 정확도가 향상되어 ATS와 다른 신경근육질환 및 심장질환과의 감별이 용이해졌습니다. 이는 전 세계에서 확인된 사례가 꾸준히 증가하고 있으며, 연구와 치료에 대한 보다 집중적인 접근을 촉진하는 데 기여하고 있습니다.

또한 희귀질환 커뮤니티의 조기 진단과 표적 치료를 위한 노력은 ATS의 인지도 향상에 직접적인 영향을 미치고 있습니다. 환자 지원 단체는 교육적 자원을 보급하고, 조기 개입 전략을 지원하며, 환자와 가족을 전문 치료 센터로 연결하는 데 있으며, 매우 중요한 역할을 하고 있습니다. 공중보건 기관들도 희귀질환 등록에 대한 투자를 늘려 ATS와 같은 질환에 대한 종합적인 데이터세트를 구축하는 데 도움을 주고 있습니다. 이러한 등록은 역학에 대한 이해를 증진시킬 뿐만 아니라, 유전형과 표현형의 상관관계 및 장기적인 질병 진행에 대한 연구에도 도움이 되고 있습니다. 현재 임상의들은 심전도 이상이나 형태학적 이상과 함께 원인 불명의 근력저하 에피소드를 보이는 환자에게 ATS를 고려하도록 권장하는 경우가 많아지고 있습니다. 그 결과, ATS는 의학적 수수께끼에서 신경근육학 및 순환기학 영역에서 충분히 인지된 증후군으로 전환되고 있으며, 보다 타겟팅된 치료 및 진단을 위한 해결책이 요구되고 있습니다.

진단 툴와 유전학적 지식이 ATS 관리 전략을 어떻게 변화시키고 있는가?

ATS의 핵심은 KCNJ2 유전자의 돌연변이이며, 이 유전자는 근육 수축과 심장 리듬 조절에 관여하는 칼륨 이온 채널을 암호화하는 유전자로, 분자 유전학과 정밀 의학의 통합으로 인해 상황이 빠르게 변화하고 있습니다. 유전자 검사를 통해 이 돌연변이를 확인하는 것은 ATS 진단의 핵심이며, 임상의는 의심되는 사례를 높은 확신을 가지고 확인할 수 있습니다. 유전자 검사는 이제 더 광범위하게 이용할 수 있고 가격도 저렴해져 가족성 패턴을 감지하고 무증상 친척에 대한 위험 평가를 유도하는 데 도움이 되고 있습니다. 이는 이 질환과 관련된 부정맥이 생명을 위협할 수 있다는 점을 고려할 때 조기 심장 모니터링 및 중재에 매우 중요합니다.

진단뿐만 아니라 유전학적 지식은 치료 접근법에도 영향을 미치고 있으며, ATS의 근본적인 분자 메커니즘을 이해함으로써 연구자들은 이온 채널 기능을 조절하는 표적 치료법을 모색하고 있습니다. 현재 치료법은 존재하지 않지만, 생활습관 개선, 약리학적 개입, 심장 모니터링 등을 결합한 맞춤 치료 계획이 보편화되고 있습니다. 예를 들어 주기성 마비 치료에는 칼륨을 보충하고, 심각한 심장 증상이 있는 환자에게는 항부정맥제나 이식형 제세동기(ICD)를 처방하는 식입니다. 웨어러블 건강 기술의 발전으로 심장 활동과 근육의 성능을 실시간으로 모니터링할 수 있게 되면서 관리가 더욱 개선되고 있습니다. 이러한 툴은 심각한 사건에 대한 조기 경고를 제공할 뿐만 아니라 장기적인 데이터 수집을 용이하게 하여 연구와 개인 맞춤형 치료에 기여하고 있습니다. 이러한 유전학, 진단학, 기술의 융합은 ATS에 대한 접근 방식에 혁명을 가져왔으며, 사후 대응이 아닌 예방적 관리를 가능하게 하고 있습니다.

ATS 치료제 개발에는 어떤 과제와 기회가 있는가?

안데르센-타윌 증후군에 대한 효과적인 치료제 개발에는 장애와 새로운 가능성이 혼재되어 있습니다. 가장 큰 과제 중 하나는 환자 수가 적고 분산되어 있으며, 대규모 임상시험을 수행하고 통계적으로 유의미한 데이터를 수집하는 것이 어렵다는 점입니다. 증상의 유형, 중증도, 빈도가 다양하다는 이 질환의 이질성은 표준화된 치료 프로토콜을 만드는 것을 더욱 복잡하게 만듭니다. 또한 ATS의 증상은 다른 질환과 중복되는 경우가 많아 진단이 지연되는 경우가 많아 조기 치료 개입의 문이 좁아지고 있습니다. 상업적 인센티브가 제한적이기 때문에 대형 제약사들은 ATS에 특화된 약물 개발에 많은 투자를 할 수 없고, 다른 질환을 대상으로 한 약물의 적응증 외 사용에 의존할 수밖에 없는 실정입니다.

이러한 장벽에도 불구하고 희귀질환 치료제의 생태계가 확장됨에 따라 낙관적인 시각이 확산되고 있습니다. 약물 재사용의 발전으로 연구자들은 기존 이온채널 조절제 및 항부정맥제의 ATS 환자에 대한 효능을 평가할 수 있게 되었습니다. 이 전략은 개발 기간과 비용을 크게 단축시켜 치료제를 시장에 출시하는 것이 더 현실적으로 가능해졌습니다. 이와 함께 환자 등록 및 국제 공동연구는 데이터와 자원을 통합하여 보다 통합된 연구 전선을 형성하고 있습니다. 규제 당국도 희귀질환 치료제 지정 및 조기 승인 절차를 통해 이 분야의 혁신에 인센티브를 제공하고 있으며, 아직 초기 단계에 있는 CRISPR 기반 유전자 편집 및 RNA 표적 치료와 같은 신기술은 장기적으로 근본적인 유전자 변이를 교정할 수 있는 잠재력을 가지고 있습니다. 잠재력을 가지고 있습니다. 이러한 발전은 패러다임의 전환을 시사하고 있으며, 도전에도 불구하고 ATS 치료의 상황이 과학, 정책, 환자들의 지지에 힘입어 의미 있는 변화의 정점에 서 있음을 시사합니다.

안데르센-타윌 증후군 시장의 성장을 가속하는 요인은 무엇인가?

안데르센-타윌 증후군 시장의 성장은 진단법 발전, 인식 개선, 치료법 탐색 확대, 의료 정책 지원 등과 관련된 몇 가지 중요한 요인에 의해 주도되고 있습니다. 그 중 가장 중요한 것은 유전자 검사의 역할로, ATS 사례의 식별을 극적으로 개선했습니다. 시퀀싱 기술이 더 쉽게 이용할 수 있게 되고 표준 진단 프로토콜에 통합됨에 따라 더 많은 환자들이 무증상 단계에서도 정확한 진단을 받고 있습니다. 이는 이 질환의 전반적인 진단 유병률을 증가시킬 뿐만 아니라, 더 많은 환자를 의료 시스템으로 끌어들여 검사, 모니터링 툴 및 치료 옵션에 대한 수요를 자극할 것입니다. 동시에 신경과 전문의, 심장 전문의, 유전학 전문의가 참여하는 다학제적 치료 접근법의 등장은 ATS 환자에게 제공할 수 있는 치료의 질을 높이고, 진단약, 심장 임플란트, 희귀질환 치료제 등 관련 시장의 성장을 더욱 촉진하고 있습니다.

희귀질환에 대한 민관의 관심도 큰 원동력이 되고 있습니다. 각국 정부는 자금 지원 프로그램, 연구 보조금, 규제 혜택 등 희귀질환 치료를 지원하기 위한 구상을 도입하고 있습니다. 이러한 지원은 생명공학 스타트업과 중견 제약사들의 ATS 분야 진출을 촉진하고, 신약 후보물질 개발 및 기존 치료법의 적응증 확대를 촉진하고 있습니다. 한편, 세계 환자 옹호 활동은 환자의 목소리가 연구 우선순위, 임상시험 설계, 자금 배분에 영향을 미치도록 함으로써 시장을 재구성하고 있습니다. 원격 심전도 모니터 및 환자 데이터 앱과 같은 디지털 건강 툴의 통합은 지속적인 증상 추적, 조기 개입 및 실제 증거 수집을 가능하게 함으로써 시장 기회를 확대하고 있습니다. 또한 1차 의료 서비스 프로바이더를 대상으로 한 교육적 노력은 ATS 증상을 조기에 인지하여 신속한 의뢰와 환자 예후 개선으로 이어질 수 있도록 돕습니다. 이러한 상호 연계된 힘은 ATS 시장의 꾸준한 성장을 가속할 뿐만 아니라, 희귀질환 치료 분야에서 환자 중심의 장기적인 기술 혁신의 토대가 되고 있습니다.

부문

질환 유형(1형 질환, 2형 질환), 유통 채널(병원 약국, 소매 약국, 온라인 유통 채널)

조사 대상 기업의 예(총 42사)

  • AbbVie Inc.
  • Advanz Pharma
  • Alembic Pharmaceuticals
  • Alexion Pharmaceuticals
  • Amgen Inc.
  • Astellas Pharma Inc.
  • AstraZeneca plc
  • Bayer AG
  • BioMarin Pharmaceutical Inc.
  • Boehringer Ingelheim
  • Bristol-Myers Squibb
  • Dr. Reddy's Laboratories Ltd.
  • Eli Lilly and Company
  • GlaxoSmithKline plc
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc.
  • Sanofi S.A.
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.

AI 통합

검증된 전문가 컨텐츠와 AI 툴에 의해 시장 정보와 경쟁 정보를 변혁합니다.

Global Industry Analysts는 LLM나 업계 고유 SLM를 조회하는 일반적인 규범에 따르는 대신에, 비디오 기록, 블로그, 검색 엔진 조사, 방대한 양 기업, 제품/서비스, 시장 데이터 등, 전 세계 전문가로부터 수집한 컨텐츠 리포지토리를 구축했습니다.

관세 영향 계수

Global Industry Analysts는 본사의 국가, 제조거점, 수출입(완제품 및 OEM)을 기반으로 기업의 경쟁력 변화를 예측했습니다. 이러한 복잡하고 다면적인 시장 역학은 수입원가(COGS) 증가, 수익성 감소, 공급망 재편 등 미시적 및 거시적 시장 역학 중에서도 특히 경쟁사들에게 영향을 미칠 것으로 예측됩니다.

목차

제1장 조사 방법

제2장 개요

  • 시장 개요
  • 주요 기업
  • 시장 동향과 촉진요인
  • 세계 시장 전망

제3장 시장 분석

  • 미국
  • 캐나다
  • 일본
  • 중국
  • 유럽
  • 프랑스
  • 독일
  • 이탈리아
  • 영국
  • 스페인
  • 러시아
  • 기타 유럽
  • 아시아태평양
  • 호주
  • 인도
  • 한국
  • 기타 아시아태평양
  • 라틴아메리카
  • 아르헨티나
  • 브라질
  • 멕시코
  • 기타 라틴아메리카
  • 중동
  • 이란
  • 이스라엘
  • 사우디아라비아
  • 아랍에미리트
  • 기타 중동
  • 아프리카

제4장 경쟁

KSA 25.07.15

Global Andersen-Tawil Syndrome (ATS) Market to Reach US$3.1 Million by 2030

The global market for Andersen-Tawil Syndrome (ATS) estimated at US$2.2 Million in the year 2024, is expected to reach US$3.1 Million by 2030, growing at a CAGR of 5.7% over the analysis period 2024-2030. Type 1 Disease, one of the segments analyzed in the report, is expected to record a 4.5% CAGR and reach US$1.8 Million by the end of the analysis period. Growth in the Type 2 Disease segment is estimated at 7.4% CAGR over the analysis period.

The U.S. Market is Estimated at US$599.5 Thousand While China is Forecast to Grow at 8.7% CAGR

The Andersen-Tawil Syndrome (ATS) market in the U.S. is estimated at US$599.5 Thousand in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$610.9 Thousand by the year 2030 trailing a CAGR of 8.7% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 2.8% and 5.5% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 3.7% CAGR.

Global Andersen-Tawil Syndrome (ATS) Market - Key Trends & Drivers Summarized

Why Is Andersen-Tawil Syndrome Garnering Increased Attention in the Rare Disease Community?

Andersen-Tawil Syndrome (ATS), though extremely rare, is drawing growing interest from researchers, clinicians, and patient advocacy groups due to its complex symptomology and diagnostic challenges. This autosomal dominant disorder-characterized by a triad of periodic paralysis, distinctive facial and skeletal features, and cardiac arrhythmias-presents significant hurdles for early detection and effective management. Traditionally underdiagnosed or misclassified due to overlapping symptoms with more common conditions, ATS is now increasingly being recognized thanks to advances in genetic testing and clinical awareness. The emergence of more refined phenotyping techniques and next-generation sequencing has improved diagnostic accuracy, making it easier to distinguish ATS from other neuromuscular or cardiac disorders. This has contributed to a steady rise in identified cases worldwide, prompting a more focused approach to research and care.

Furthermore, the rare disease community’s efforts to push for earlier diagnosis and targeted treatment for orphan diseases are having a direct impact on ATS awareness. Patient advocacy groups are playing a pivotal role in disseminating educational resources, supporting early intervention strategies, and connecting affected families with specialized care centers. Public health agencies, too, are investing more in rare disease registries, which are helping build comprehensive datasets on conditions like ATS. These registries not only improve epidemiological understanding but also guide research into genotype-phenotype correlations and long-term disease progression. Clinicians are now more frequently encouraged to consider ATS in patients presenting with unexplained episodes of muscle weakness alongside ECG abnormalities or dysmorphic features. As a result, ATS is transitioning from being a medical enigma to a well-recognized syndrome within the neuromuscular and cardiology communities, setting the stage for more targeted therapeutic and diagnostic solutions.

How Are Diagnostic Tools and Genetic Insights Transforming ATS Management Strategies?

The landscape for diagnosing and managing Andersen-Tawil Syndrome is evolving rapidly, thanks in large part to the growing integration of molecular genetics and precision medicine. At the heart of ATS lies a mutation in the KCNJ2 gene, which encodes a potassium ion channel involved in regulating both muscle contraction and cardiac rhythm. Identifying this mutation through genetic testing has become a cornerstone of ATS diagnosis, enabling clinicians to confirm suspected cases with a high degree of certainty. Genetic testing is now more widely available and affordable, helping detect familial patterns and guiding risk assessment for asymptomatic relatives. This has led to an increase in pre-symptomatic diagnoses, which is critical for early cardiac monitoring and intervention, given the life-threatening potential of arrhythmias associated with the disorder.

Beyond diagnosis, genetic insights are also influencing treatment approaches. By understanding the molecular mechanisms underlying ATS, researchers are exploring targeted therapies that modulate ion channel function. Although no cure currently exists, individualized treatment plans are becoming more common, incorporating a mix of lifestyle modifications, pharmacological interventions, and cardiac surveillance. For example, potassium supplementation is used to manage periodic paralysis, while antiarrhythmic drugs and implantable cardioverter-defibrillators (ICDs) are prescribed in patients with severe cardiac manifestations. Advances in wearable health technology have further improved management, allowing real-time monitoring of cardiac activity and muscle performance. These tools not only provide early warnings for serious events but also facilitate long-term data collection, contributing to research and personalized care. This fusion of genetics, diagnostics, and technology is revolutionizing the way ATS is approached, making management more proactive rather than reactive.

What Challenges and Opportunities Exist in the Development of ATS Therapeutics?

Developing effective therapeutics for Andersen-Tawil Syndrome presents a unique mix of obstacles and emerging possibilities, largely due to the syndrome’s rarity and clinical variability. One of the foremost challenges lies in the small and dispersed patient population, which makes it difficult to conduct large-scale clinical trials and gather statistically significant data. The heterogeneous nature of the disease-where symptoms can range widely in type, severity, and frequency-further complicates the creation of standardized treatment protocols. Moreover, the overlap of ATS symptoms with other disorders often delays diagnosis, reducing the window for early therapeutic intervention. Limited commercial incentives have historically discouraged major pharmaceutical players from investing heavily in ATS-specific drug development, leading to a reliance on off-label use of drugs intended for other conditions.

Despite these barriers, there is a growing wave of optimism driven by the expanding rare disease drug ecosystem. Advances in drug repurposing are enabling researchers to evaluate existing ion channel modulators and antiarrhythmic agents for efficacy in ATS patients. This strategy significantly reduces development timelines and costs, making it more feasible to bring treatments to market. In parallel, patient registries and international collaborations are helping to consolidate data and resources, creating a more unified research front. Regulatory bodies are also providing pathways like orphan drug designations and accelerated approval processes to incentivize innovation in this space. Emerging technologies such as CRISPR-based gene editing and RNA-targeted therapies, while still in early stages, hold potential for long-term correction of the underlying genetic mutation. These developments signal a paradigm shift, suggesting that despite its challenges, the ATS therapeutic landscape is on the cusp of meaningful change, driven by science, policy, and patient advocacy.

Which Factors Are Driving Growth in the Andersen-Tawil Syndrome Market?

The growth in the Andersen-Tawil Syndrome market is driven by several critical factors linked to advances in diagnostics, increasing awareness, expanding therapeutic exploration, and supportive healthcare policy. At the forefront is the role of genetic testing, which has dramatically improved the identification of ATS cases. As sequencing technologies become more accessible and are integrated into standard diagnostic protocols, more patients are being correctly diagnosed, even during asymptomatic phases. This not only increases the overall diagnosed prevalence of the condition but also brings a larger patient population into the healthcare system, stimulating demand for medical consultations, monitoring tools, and therapeutic options. At the same time, the rise in multidisciplinary care approaches-bringing together neurologists, cardiologists, and geneticists-is elevating the quality of care available for ATS patients, further reinforcing the growth of associated markets such as diagnostics, cardiac implants, and rare disease therapeutics.

Public and private sector interest in rare diseases is another major driver. Governments are introducing initiatives to support orphan disease treatment, including funding programs, research grants, and access to regulatory incentives. This support has encouraged biotech startups and mid-sized pharmaceutical firms to enter the ATS space, developing novel drug candidates or adapting existing therapies. Meanwhile, global patient advocacy is reshaping the market by ensuring that patient voices influence research priorities, clinical trial design, and funding allocations. The integration of digital health tools-such as remote ECG monitors and patient data apps-is also expanding market opportunities by enabling ongoing symptom tracking, early intervention, and real-world evidence collection. Furthermore, educational efforts targeted at primary care providers are increasing early recognition of ATS symptoms, which leads to faster referrals and better patient outcomes. These interlinked forces are not only driving steady growth in the ATS market but are also setting the foundation for long-term, patient-centric innovation in rare disease care.

SCOPE OF STUDY:

The report analyzes the Andersen-Tawil Syndrome (ATS) market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Disease Type (Type 1 Disease, Type 2 Disease); Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Distribution Channel)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 42 Featured) -

  • AbbVie Inc.
  • Advanz Pharma
  • Alembic Pharmaceuticals
  • Alexion Pharmaceuticals
  • Amgen Inc.
  • Astellas Pharma Inc.
  • AstraZeneca plc
  • Bayer AG
  • BioMarin Pharmaceutical Inc.
  • Boehringer Ingelheim
  • Bristol-Myers Squibb
  • Dr. Reddy's Laboratories Ltd.
  • Eli Lilly and Company
  • GlaxoSmithKline plc
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc.
  • Sanofi S.A.
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Tariff Impact on Global Supply Chain Patterns
    • Andersen-Tawil Syndrome (ATS) - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Awareness and Diagnostic Accuracy Spur Early Identification and Clinical Management of Andersen-Tawil Syndrome (ATS)
    • Advancements in Genetic Testing Technologies Strengthen the Business Case for Precision Diagnosis in Rare Channelopathies
    • Here's How Increased Inclusion of ATS in Neuromuscular Disease Panels Expands the Addressable Patient Pool
    • Growing Interest in Potassium Channelopathies Drives Research into Targeted Therapeutic Approaches for ATS
    • Here's the Story: Integration of Cardiac Monitoring and Neurological Assessment Enhances Holistic Management Strategies
    • Improved Access to Multidisciplinary Care Models Sustains Growth in Specialist Referral and Treatment Uptake
    • Rising Use of Off-Label Therapies and Symptom-Based Management Drives Demand for Personalized Care Plans
    • Global Expansion of Orphan Drug Programs Generates Opportunities for Novel ATS-Specific Therapeutics
    • Technological Innovation in Wearable ECG and Remote Monitoring Tools Supports Early Detection of Arrhythmic Events
    • Growing Focus on Pediatric Neurology and Genetic Counseling Strengthens Early Intervention Strategies for ATS
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Andersen-Tawil Syndrome (ATS) Market Analysis of Annual Sales in US$ for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Andersen-Tawil Syndrome (ATS) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Andersen-Tawil Syndrome (ATS) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 4: World 16-Year Perspective for Andersen-Tawil Syndrome (ATS) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Type 1 Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Type 1 Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 7: World 16-Year Perspective for Type 1 Disease by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Type 2 Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Type 2 Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 10: World 16-Year Perspective for Type 2 Disease by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 13: World 16-Year Perspective for Hospital Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 16: World 16-Year Perspective for Retail Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Online Distribution Channel by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Online Distribution Channel by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 19: World 16-Year Perspective for Online Distribution Channel by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Andersen-Tawil Syndrome (ATS) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 20: USA Recent Past, Current & Future Analysis for Andersen-Tawil Syndrome (ATS) by Disease Type - Type 1 Disease and Type 2 Disease - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 21: USA Historic Review for Andersen-Tawil Syndrome (ATS) by Disease Type - Type 1 Disease and Type 2 Disease Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 22: USA 16-Year Perspective for Andersen-Tawil Syndrome (ATS) by Disease Type - Percentage Breakdown of Value Sales for Type 1 Disease and Type 2 Disease for the Years 2014, 2025 & 2030
    • TABLE 23: USA Recent Past, Current & Future Analysis for Andersen-Tawil Syndrome (ATS) by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 24: USA Historic Review for Andersen-Tawil Syndrome (ATS) by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 25: USA 16-Year Perspective for Andersen-Tawil Syndrome (ATS) by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • CANADA
    • TABLE 26: Canada Recent Past, Current & Future Analysis for Andersen-Tawil Syndrome (ATS) by Disease Type - Type 1 Disease and Type 2 Disease - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 27: Canada Historic Review for Andersen-Tawil Syndrome (ATS) by Disease Type - Type 1 Disease and Type 2 Disease Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 28: Canada 16-Year Perspective for Andersen-Tawil Syndrome (ATS) by Disease Type - Percentage Breakdown of Value Sales for Type 1 Disease and Type 2 Disease for the Years 2014, 2025 & 2030
    • TABLE 29: Canada Recent Past, Current & Future Analysis for Andersen-Tawil Syndrome (ATS) by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 30: Canada Historic Review for Andersen-Tawil Syndrome (ATS) by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 31: Canada 16-Year Perspective for Andersen-Tawil Syndrome (ATS) by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • JAPAN
    • Andersen-Tawil Syndrome (ATS) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 32: Japan Recent Past, Current & Future Analysis for Andersen-Tawil Syndrome (ATS) by Disease Type - Type 1 Disease and Type 2 Disease - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 33: Japan Historic Review for Andersen-Tawil Syndrome (ATS) by Disease Type - Type 1 Disease and Type 2 Disease Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 34: Japan 16-Year Perspective for Andersen-Tawil Syndrome (ATS) by Disease Type - Percentage Breakdown of Value Sales for Type 1 Disease and Type 2 Disease for the Years 2014, 2025 & 2030
    • TABLE 35: Japan Recent Past, Current & Future Analysis for Andersen-Tawil Syndrome (ATS) by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 36: Japan Historic Review for Andersen-Tawil Syndrome (ATS) by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 37: Japan 16-Year Perspective for Andersen-Tawil Syndrome (ATS) by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • CHINA
    • Andersen-Tawil Syndrome (ATS) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 38: China Recent Past, Current & Future Analysis for Andersen-Tawil Syndrome (ATS) by Disease Type - Type 1 Disease and Type 2 Disease - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 39: China Historic Review for Andersen-Tawil Syndrome (ATS) by Disease Type - Type 1 Disease and Type 2 Disease Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 40: China 16-Year Perspective for Andersen-Tawil Syndrome (ATS) by Disease Type - Percentage Breakdown of Value Sales for Type 1 Disease and Type 2 Disease for the Years 2014, 2025 & 2030
    • TABLE 41: China Recent Past, Current & Future Analysis for Andersen-Tawil Syndrome (ATS) by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 42: China Historic Review for Andersen-Tawil Syndrome (ATS) by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 43: China 16-Year Perspective for Andersen-Tawil Syndrome (ATS) by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • EUROPE
    • Andersen-Tawil Syndrome (ATS) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 44: Europe Recent Past, Current & Future Analysis for Andersen-Tawil Syndrome (ATS) by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 45: Europe Historic Review for Andersen-Tawil Syndrome (ATS) by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 46: Europe 16-Year Perspective for Andersen-Tawil Syndrome (ATS) by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2025 & 2030
    • TABLE 47: Europe Recent Past, Current & Future Analysis for Andersen-Tawil Syndrome (ATS) by Disease Type - Type 1 Disease and Type 2 Disease - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 48: Europe Historic Review for Andersen-Tawil Syndrome (ATS) by Disease Type - Type 1 Disease and Type 2 Disease Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 49: Europe 16-Year Perspective for Andersen-Tawil Syndrome (ATS) by Disease Type - Percentage Breakdown of Value Sales for Type 1 Disease and Type 2 Disease for the Years 2014, 2025 & 2030
    • TABLE 50: Europe Recent Past, Current & Future Analysis for Andersen-Tawil Syndrome (ATS) by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Europe Historic Review for Andersen-Tawil Syndrome (ATS) by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 52: Europe 16-Year Perspective for Andersen-Tawil Syndrome (ATS) by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • FRANCE
    • Andersen-Tawil Syndrome (ATS) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 53: France Recent Past, Current & Future Analysis for Andersen-Tawil Syndrome (ATS) by Disease Type - Type 1 Disease and Type 2 Disease - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 54: France Historic Review for Andersen-Tawil Syndrome (ATS) by Disease Type - Type 1 Disease and Type 2 Disease Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 55: France 16-Year Perspective for Andersen-Tawil Syndrome (ATS) by Disease Type - Percentage Breakdown of Value Sales for Type 1 Disease and Type 2 Disease for the Years 2014, 2025 & 2030
    • TABLE 56: France Recent Past, Current & Future Analysis for Andersen-Tawil Syndrome (ATS) by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 57: France Historic Review for Andersen-Tawil Syndrome (ATS) by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 58: France 16-Year Perspective for Andersen-Tawil Syndrome (ATS) by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • GERMANY
    • Andersen-Tawil Syndrome (ATS) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 59: Germany Recent Past, Current & Future Analysis for Andersen-Tawil Syndrome (ATS) by Disease Type - Type 1 Disease and Type 2 Disease - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 60: Germany Historic Review for Andersen-Tawil Syndrome (ATS) by Disease Type - Type 1 Disease and Type 2 Disease Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 61: Germany 16-Year Perspective for Andersen-Tawil Syndrome (ATS) by Disease Type - Percentage Breakdown of Value Sales for Type 1 Disease and Type 2 Disease for the Years 2014, 2025 & 2030
    • TABLE 62: Germany Recent Past, Current & Future Analysis for Andersen-Tawil Syndrome (ATS) by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Germany Historic Review for Andersen-Tawil Syndrome (ATS) by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 64: Germany 16-Year Perspective for Andersen-Tawil Syndrome (ATS) by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • ITALY
    • TABLE 65: Italy Recent Past, Current & Future Analysis for Andersen-Tawil Syndrome (ATS) by Disease Type - Type 1 Disease and Type 2 Disease - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 66: Italy Historic Review for Andersen-Tawil Syndrome (ATS) by Disease Type - Type 1 Disease and Type 2 Disease Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 67: Italy 16-Year Perspective for Andersen-Tawil Syndrome (ATS) by Disease Type - Percentage Breakdown of Value Sales for Type 1 Disease and Type 2 Disease for the Years 2014, 2025 & 2030
    • TABLE 68: Italy Recent Past, Current & Future Analysis for Andersen-Tawil Syndrome (ATS) by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Italy Historic Review for Andersen-Tawil Syndrome (ATS) by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 70: Italy 16-Year Perspective for Andersen-Tawil Syndrome (ATS) by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • UNITED KINGDOM
    • Andersen-Tawil Syndrome (ATS) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 71: UK Recent Past, Current & Future Analysis for Andersen-Tawil Syndrome (ATS) by Disease Type - Type 1 Disease and Type 2 Disease - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 72: UK Historic Review for Andersen-Tawil Syndrome (ATS) by Disease Type - Type 1 Disease and Type 2 Disease Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 73: UK 16-Year Perspective for Andersen-Tawil Syndrome (ATS) by Disease Type - Percentage Breakdown of Value Sales for Type 1 Disease and Type 2 Disease for the Years 2014, 2025 & 2030
    • TABLE 74: UK Recent Past, Current & Future Analysis for Andersen-Tawil Syndrome (ATS) by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 75: UK Historic Review for Andersen-Tawil Syndrome (ATS) by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 76: UK 16-Year Perspective for Andersen-Tawil Syndrome (ATS) by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • SPAIN
    • TABLE 77: Spain Recent Past, Current & Future Analysis for Andersen-Tawil Syndrome (ATS) by Disease Type - Type 1 Disease and Type 2 Disease - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 78: Spain Historic Review for Andersen-Tawil Syndrome (ATS) by Disease Type - Type 1 Disease and Type 2 Disease Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 79: Spain 16-Year Perspective for Andersen-Tawil Syndrome (ATS) by Disease Type - Percentage Breakdown of Value Sales for Type 1 Disease and Type 2 Disease for the Years 2014, 2025 & 2030
    • TABLE 80: Spain Recent Past, Current & Future Analysis for Andersen-Tawil Syndrome (ATS) by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Spain Historic Review for Andersen-Tawil Syndrome (ATS) by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 82: Spain 16-Year Perspective for Andersen-Tawil Syndrome (ATS) by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • RUSSIA
    • TABLE 83: Russia Recent Past, Current & Future Analysis for Andersen-Tawil Syndrome (ATS) by Disease Type - Type 1 Disease and Type 2 Disease - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 84: Russia Historic Review for Andersen-Tawil Syndrome (ATS) by Disease Type - Type 1 Disease and Type 2 Disease Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 85: Russia 16-Year Perspective for Andersen-Tawil Syndrome (ATS) by Disease Type - Percentage Breakdown of Value Sales for Type 1 Disease and Type 2 Disease for the Years 2014, 2025 & 2030
    • TABLE 86: Russia Recent Past, Current & Future Analysis for Andersen-Tawil Syndrome (ATS) by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Russia Historic Review for Andersen-Tawil Syndrome (ATS) by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 88: Russia 16-Year Perspective for Andersen-Tawil Syndrome (ATS) by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • REST OF EUROPE
    • TABLE 89: Rest of Europe Recent Past, Current & Future Analysis for Andersen-Tawil Syndrome (ATS) by Disease Type - Type 1 Disease and Type 2 Disease - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Rest of Europe Historic Review for Andersen-Tawil Syndrome (ATS) by Disease Type - Type 1 Disease and Type 2 Disease Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 91: Rest of Europe 16-Year Perspective for Andersen-Tawil Syndrome (ATS) by Disease Type - Percentage Breakdown of Value Sales for Type 1 Disease and Type 2 Disease for the Years 2014, 2025 & 2030
    • TABLE 92: Rest of Europe Recent Past, Current & Future Analysis for Andersen-Tawil Syndrome (ATS) by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Rest of Europe Historic Review for Andersen-Tawil Syndrome (ATS) by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 94: Rest of Europe 16-Year Perspective for Andersen-Tawil Syndrome (ATS) by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • ASIA-PACIFIC
    • Andersen-Tawil Syndrome (ATS) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 95: Asia-Pacific Recent Past, Current & Future Analysis for Andersen-Tawil Syndrome (ATS) by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 96: Asia-Pacific Historic Review for Andersen-Tawil Syndrome (ATS) by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 97: Asia-Pacific 16-Year Perspective for Andersen-Tawil Syndrome (ATS) by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2025 & 2030
    • TABLE 98: Asia-Pacific Recent Past, Current & Future Analysis for Andersen-Tawil Syndrome (ATS) by Disease Type - Type 1 Disease and Type 2 Disease - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Asia-Pacific Historic Review for Andersen-Tawil Syndrome (ATS) by Disease Type - Type 1 Disease and Type 2 Disease Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 100: Asia-Pacific 16-Year Perspective for Andersen-Tawil Syndrome (ATS) by Disease Type - Percentage Breakdown of Value Sales for Type 1 Disease and Type 2 Disease for the Years 2014, 2025 & 2030
    • TABLE 101: Asia-Pacific Recent Past, Current & Future Analysis for Andersen-Tawil Syndrome (ATS) by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Asia-Pacific Historic Review for Andersen-Tawil Syndrome (ATS) by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 103: Asia-Pacific 16-Year Perspective for Andersen-Tawil Syndrome (ATS) by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • AUSTRALIA
    • Andersen-Tawil Syndrome (ATS) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 104: Australia Recent Past, Current & Future Analysis for Andersen-Tawil Syndrome (ATS) by Disease Type - Type 1 Disease and Type 2 Disease - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Australia Historic Review for Andersen-Tawil Syndrome (ATS) by Disease Type - Type 1 Disease and Type 2 Disease Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 106: Australia 16-Year Perspective for Andersen-Tawil Syndrome (ATS) by Disease Type - Percentage Breakdown of Value Sales for Type 1 Disease and Type 2 Disease for the Years 2014, 2025 & 2030
    • TABLE 107: Australia Recent Past, Current & Future Analysis for Andersen-Tawil Syndrome (ATS) by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 108: Australia Historic Review for Andersen-Tawil Syndrome (ATS) by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 109: Australia 16-Year Perspective for Andersen-Tawil Syndrome (ATS) by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • INDIA
    • Andersen-Tawil Syndrome (ATS) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 110: India Recent Past, Current & Future Analysis for Andersen-Tawil Syndrome (ATS) by Disease Type - Type 1 Disease and Type 2 Disease - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 111: India Historic Review for Andersen-Tawil Syndrome (ATS) by Disease Type - Type 1 Disease and Type 2 Disease Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 112: India 16-Year Perspective for Andersen-Tawil Syndrome (ATS) by Disease Type - Percentage Breakdown of Value Sales for Type 1 Disease and Type 2 Disease for the Years 2014, 2025 & 2030
    • TABLE 113: India Recent Past, Current & Future Analysis for Andersen-Tawil Syndrome (ATS) by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 114: India Historic Review for Andersen-Tawil Syndrome (ATS) by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 115: India 16-Year Perspective for Andersen-Tawil Syndrome (ATS) by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • SOUTH KOREA
    • TABLE 116: South Korea Recent Past, Current & Future Analysis for Andersen-Tawil Syndrome (ATS) by Disease Type - Type 1 Disease and Type 2 Disease - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 117: South Korea Historic Review for Andersen-Tawil Syndrome (ATS) by Disease Type - Type 1 Disease and Type 2 Disease Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 118: South Korea 16-Year Perspective for Andersen-Tawil Syndrome (ATS) by Disease Type - Percentage Breakdown of Value Sales for Type 1 Disease and Type 2 Disease for the Years 2014, 2025 & 2030
    • TABLE 119: South Korea Recent Past, Current & Future Analysis for Andersen-Tawil Syndrome (ATS) by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 120: South Korea Historic Review for Andersen-Tawil Syndrome (ATS) by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 121: South Korea 16-Year Perspective for Andersen-Tawil Syndrome (ATS) by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 122: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Andersen-Tawil Syndrome (ATS) by Disease Type - Type 1 Disease and Type 2 Disease - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 123: Rest of Asia-Pacific Historic Review for Andersen-Tawil Syndrome (ATS) by Disease Type - Type 1 Disease and Type 2 Disease Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 124: Rest of Asia-Pacific 16-Year Perspective for Andersen-Tawil Syndrome (ATS) by Disease Type - Percentage Breakdown of Value Sales for Type 1 Disease and Type 2 Disease for the Years 2014, 2025 & 2030
    • TABLE 125: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Andersen-Tawil Syndrome (ATS) by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 126: Rest of Asia-Pacific Historic Review for Andersen-Tawil Syndrome (ATS) by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 127: Rest of Asia-Pacific 16-Year Perspective for Andersen-Tawil Syndrome (ATS) by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • LATIN AMERICA
    • Andersen-Tawil Syndrome (ATS) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 128: Latin America Recent Past, Current & Future Analysis for Andersen-Tawil Syndrome (ATS) by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 129: Latin America Historic Review for Andersen-Tawil Syndrome (ATS) by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 130: Latin America 16-Year Perspective for Andersen-Tawil Syndrome (ATS) by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2025 & 2030
    • TABLE 131: Latin America Recent Past, Current & Future Analysis for Andersen-Tawil Syndrome (ATS) by Disease Type - Type 1 Disease and Type 2 Disease - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Latin America Historic Review for Andersen-Tawil Syndrome (ATS) by Disease Type - Type 1 Disease and Type 2 Disease Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 133: Latin America 16-Year Perspective for Andersen-Tawil Syndrome (ATS) by Disease Type - Percentage Breakdown of Value Sales for Type 1 Disease and Type 2 Disease for the Years 2014, 2025 & 2030
    • TABLE 134: Latin America Recent Past, Current & Future Analysis for Andersen-Tawil Syndrome (ATS) by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Latin America Historic Review for Andersen-Tawil Syndrome (ATS) by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 136: Latin America 16-Year Perspective for Andersen-Tawil Syndrome (ATS) by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • ARGENTINA
    • TABLE 137: Argentina Recent Past, Current & Future Analysis for Andersen-Tawil Syndrome (ATS) by Disease Type - Type 1 Disease and Type 2 Disease - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Argentina Historic Review for Andersen-Tawil Syndrome (ATS) by Disease Type - Type 1 Disease and Type 2 Disease Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 139: Argentina 16-Year Perspective for Andersen-Tawil Syndrome (ATS) by Disease Type - Percentage Breakdown of Value Sales for Type 1 Disease and Type 2 Disease for the Years 2014, 2025 & 2030
    • TABLE 140: Argentina Recent Past, Current & Future Analysis for Andersen-Tawil Syndrome (ATS) by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Argentina Historic Review for Andersen-Tawil Syndrome (ATS) by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 142: Argentina 16-Year Perspective for Andersen-Tawil Syndrome (ATS) by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • BRAZIL
    • TABLE 143: Brazil Recent Past, Current & Future Analysis for Andersen-Tawil Syndrome (ATS) by Disease Type - Type 1 Disease and Type 2 Disease - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Brazil Historic Review for Andersen-Tawil Syndrome (ATS) by Disease Type - Type 1 Disease and Type 2 Disease Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 145: Brazil 16-Year Perspective for Andersen-Tawil Syndrome (ATS) by Disease Type - Percentage Breakdown of Value Sales for Type 1 Disease and Type 2 Disease for the Years 2014, 2025 & 2030
    • TABLE 146: Brazil Recent Past, Current & Future Analysis for Andersen-Tawil Syndrome (ATS) by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Brazil Historic Review for Andersen-Tawil Syndrome (ATS) by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 148: Brazil 16-Year Perspective for Andersen-Tawil Syndrome (ATS) by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • MEXICO
    • TABLE 149: Mexico Recent Past, Current & Future Analysis for Andersen-Tawil Syndrome (ATS) by Disease Type - Type 1 Disease and Type 2 Disease - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Mexico Historic Review for Andersen-Tawil Syndrome (ATS) by Disease Type - Type 1 Disease and Type 2 Disease Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 151: Mexico 16-Year Perspective for Andersen-Tawil Syndrome (ATS) by Disease Type - Percentage Breakdown of Value Sales for Type 1 Disease and Type 2 Disease for the Years 2014, 2025 & 2030
    • TABLE 152: Mexico Recent Past, Current & Future Analysis for Andersen-Tawil Syndrome (ATS) by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Mexico Historic Review for Andersen-Tawil Syndrome (ATS) by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 154: Mexico 16-Year Perspective for Andersen-Tawil Syndrome (ATS) by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 155: Rest of Latin America Recent Past, Current & Future Analysis for Andersen-Tawil Syndrome (ATS) by Disease Type - Type 1 Disease and Type 2 Disease - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Rest of Latin America Historic Review for Andersen-Tawil Syndrome (ATS) by Disease Type - Type 1 Disease and Type 2 Disease Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 157: Rest of Latin America 16-Year Perspective for Andersen-Tawil Syndrome (ATS) by Disease Type - Percentage Breakdown of Value Sales for Type 1 Disease and Type 2 Disease for the Years 2014, 2025 & 2030
    • TABLE 158: Rest of Latin America Recent Past, Current & Future Analysis for Andersen-Tawil Syndrome (ATS) by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Rest of Latin America Historic Review for Andersen-Tawil Syndrome (ATS) by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 160: Rest of Latin America 16-Year Perspective for Andersen-Tawil Syndrome (ATS) by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • MIDDLE EAST
    • Andersen-Tawil Syndrome (ATS) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 161: Middle East Recent Past, Current & Future Analysis for Andersen-Tawil Syndrome (ATS) by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 162: Middle East Historic Review for Andersen-Tawil Syndrome (ATS) by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 163: Middle East 16-Year Perspective for Andersen-Tawil Syndrome (ATS) by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2025 & 2030
    • TABLE 164: Middle East Recent Past, Current & Future Analysis for Andersen-Tawil Syndrome (ATS) by Disease Type - Type 1 Disease and Type 2 Disease - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 165: Middle East Historic Review for Andersen-Tawil Syndrome (ATS) by Disease Type - Type 1 Disease and Type 2 Disease Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 166: Middle East 16-Year Perspective for Andersen-Tawil Syndrome (ATS) by Disease Type - Percentage Breakdown of Value Sales for Type 1 Disease and Type 2 Disease for the Years 2014, 2025 & 2030
    • TABLE 167: Middle East Recent Past, Current & Future Analysis for Andersen-Tawil Syndrome (ATS) by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 168: Middle East Historic Review for Andersen-Tawil Syndrome (ATS) by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 169: Middle East 16-Year Perspective for Andersen-Tawil Syndrome (ATS) by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • IRAN
    • TABLE 170: Iran Recent Past, Current & Future Analysis for Andersen-Tawil Syndrome (ATS) by Disease Type - Type 1 Disease and Type 2 Disease - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 171: Iran Historic Review for Andersen-Tawil Syndrome (ATS) by Disease Type - Type 1 Disease and Type 2 Disease Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 172: Iran 16-Year Perspective for Andersen-Tawil Syndrome (ATS) by Disease Type - Percentage Breakdown of Value Sales for Type 1 Disease and Type 2 Disease for the Years 2014, 2025 & 2030
    • TABLE 173: Iran Recent Past, Current & Future Analysis for Andersen-Tawil Syndrome (ATS) by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 174: Iran Historic Review for Andersen-Tawil Syndrome (ATS) by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 175: Iran 16-Year Perspective for Andersen-Tawil Syndrome (ATS) by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • ISRAEL
    • TABLE 176: Israel Recent Past, Current & Future Analysis for Andersen-Tawil Syndrome (ATS) by Disease Type - Type 1 Disease and Type 2 Disease - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 177: Israel Historic Review for Andersen-Tawil Syndrome (ATS) by Disease Type - Type 1 Disease and Type 2 Disease Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 178: Israel 16-Year Perspective for Andersen-Tawil Syndrome (ATS) by Disease Type - Percentage Breakdown of Value Sales for Type 1 Disease and Type 2 Disease for the Years 2014, 2025 & 2030
    • TABLE 179: Israel Recent Past, Current & Future Analysis for Andersen-Tawil Syndrome (ATS) by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 180: Israel Historic Review for Andersen-Tawil Syndrome (ATS) by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 181: Israel 16-Year Perspective for Andersen-Tawil Syndrome (ATS) by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 182: Saudi Arabia Recent Past, Current & Future Analysis for Andersen-Tawil Syndrome (ATS) by Disease Type - Type 1 Disease and Type 2 Disease - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 183: Saudi Arabia Historic Review for Andersen-Tawil Syndrome (ATS) by Disease Type - Type 1 Disease and Type 2 Disease Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 184: Saudi Arabia 16-Year Perspective for Andersen-Tawil Syndrome (ATS) by Disease Type - Percentage Breakdown of Value Sales for Type 1 Disease and Type 2 Disease for the Years 2014, 2025 & 2030
    • TABLE 185: Saudi Arabia Recent Past, Current & Future Analysis for Andersen-Tawil Syndrome (ATS) by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 186: Saudi Arabia Historic Review for Andersen-Tawil Syndrome (ATS) by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 187: Saudi Arabia 16-Year Perspective for Andersen-Tawil Syndrome (ATS) by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 188: UAE Recent Past, Current & Future Analysis for Andersen-Tawil Syndrome (ATS) by Disease Type - Type 1 Disease and Type 2 Disease - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 189: UAE Historic Review for Andersen-Tawil Syndrome (ATS) by Disease Type - Type 1 Disease and Type 2 Disease Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 190: UAE 16-Year Perspective for Andersen-Tawil Syndrome (ATS) by Disease Type - Percentage Breakdown of Value Sales for Type 1 Disease and Type 2 Disease for the Years 2014, 2025 & 2030
    • TABLE 191: UAE Recent Past, Current & Future Analysis for Andersen-Tawil Syndrome (ATS) by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 192: UAE Historic Review for Andersen-Tawil Syndrome (ATS) by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 193: UAE 16-Year Perspective for Andersen-Tawil Syndrome (ATS) by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 194: Rest of Middle East Recent Past, Current & Future Analysis for Andersen-Tawil Syndrome (ATS) by Disease Type - Type 1 Disease and Type 2 Disease - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 195: Rest of Middle East Historic Review for Andersen-Tawil Syndrome (ATS) by Disease Type - Type 1 Disease and Type 2 Disease Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 196: Rest of Middle East 16-Year Perspective for Andersen-Tawil Syndrome (ATS) by Disease Type - Percentage Breakdown of Value Sales for Type 1 Disease and Type 2 Disease for the Years 2014, 2025 & 2030
    • TABLE 197: Rest of Middle East Recent Past, Current & Future Analysis for Andersen-Tawil Syndrome (ATS) by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 198: Rest of Middle East Historic Review for Andersen-Tawil Syndrome (ATS) by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 199: Rest of Middle East 16-Year Perspective for Andersen-Tawil Syndrome (ATS) by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030
  • AFRICA
    • Andersen-Tawil Syndrome (ATS) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 200: Africa Recent Past, Current & Future Analysis for Andersen-Tawil Syndrome (ATS) by Disease Type - Type 1 Disease and Type 2 Disease - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 201: Africa Historic Review for Andersen-Tawil Syndrome (ATS) by Disease Type - Type 1 Disease and Type 2 Disease Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 202: Africa 16-Year Perspective for Andersen-Tawil Syndrome (ATS) by Disease Type - Percentage Breakdown of Value Sales for Type 1 Disease and Type 2 Disease for the Years 2014, 2025 & 2030
    • TABLE 203: Africa Recent Past, Current & Future Analysis for Andersen-Tawil Syndrome (ATS) by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Africa Historic Review for Andersen-Tawil Syndrome (ATS) by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 205: Africa 16-Year Perspective for Andersen-Tawil Syndrome (ATS) by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Distribution Channel for the Years 2014, 2025 & 2030

IV. COMPETITION

샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제